HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $47
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Immunovant (NASDAQ:IMVT) and raises the price target from $29 to $47.
October 24, 2023 | 10:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunovant's price target has been raised from $29 to $47 by HC Wainwright & Co., maintaining a 'Buy' rating.
The raised price target indicates the analyst's increased confidence in the company's future performance. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100